ArticlePLOS global public health2026
Evaluating a biochemical TB medication adherence test: Insights from image-based reporting through a patient companion app.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tuberculosis (TB) treatment requires strict adherence over the long course of treatment. To support adherence, we developed the TB Treatment Support Tools (TB-TST), which combines a urine-based lateral flow assay (LFA) with a mobile application for patient education, support, and communication with treatment supporters. In a pragmatic randomized controlled trial participants uploaded images of the LFA. A blue-purple color change indicates detection of an isoniazid metabolite consistent with recent medication ingestion. This study assessed real-world interpretability and usability of the TB-TST LFA by analyzing the quality and characteristics of user-submitted images. We conducted structured qualitative coding (visual content analysis) of 1,655 submitted test images to identify recurring issues affecting interpretation. Eligible participants were aged 16 or older, newly diagnosed with TB, and had access to a mobile phone. An iteratively developed codebook identified three primary issue categories: 1) color variations in the test or control strip, 2) photo quality issues, and 3) test cartridge/test-strip artifacts. Most (72%) images were consistent with a clear positive (blue-purple) color change or clear negative. Variations that were not clear positives included no color change (white), yellow/orange, and green/teal hues. Blurriness was the most common image quality issue. The most common test artifact was visual evidence consistent with dye bleed/possible cross-strip contamination between the control and the test strips. Despite challenges in image submission and test appearance, relatively few images were difficult to interpret, supporting the feasibility of user-submitted LFA images for monitoring recent isoniazid ingestion. Opportunities to improve performance and usability include enhanced user guidance for image capture, refinement to cartridge design to reduce artifacts, clearer interpretation protocols for atypical color outcomes, and automated image-based reading. Integrating qualitative image analysis with engineering design principles can inform user-centered improvements to home-based LFAs connected to digital adherence technologies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.